27.08.2012 - The German antibody specialist Wilex AG has completed a capital increase to strengthen its capital base. The biotech sold 6.5 million new shares at a price of €3.70.
However not all the shares were sold for cash. As contribution in kind, the company’s largest shareholder Dievini Hopp BioTech Holding GmbH, the investment vehicle of the billionaire and SAP founder Dietmar Hopp, converted an existing loan granted to Wilex amounting to approximately €7.8m to 2.1 million new shares. This represents 32.5% of the total volume of the capital increase.This reduces Wilex' financial liabilities without adversely affecting cash reserves. Finally, Wilex receives gross proceeds of around €16.1m from the cash portion of the transaction. The company now owns about €24m in cash. Wilex runs a number of early and mid-stage clinical trials. However, the most important one is the phase III with the kidney cancer antibody Rencarex. Results for the test with the anti-EpCAM-mAb are anticipated for the end of this year. Rencarex is partnered with Prometheus Labs in the US.